At 125, aspirin still represents the cornerstone of anti-platelet therapy for the acute treatment
and long-term prevention of atherothrombosis. The development of a selective regimen of …

Colorectal cancer (CRC) is the third most common type of cancer worldwide. Screening
measures are far from adequate and not widely available in resource-poor settings. Primary …

Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially aspirin,
prevents cancer development continues to accumulate. The data are particularly convincing …

The seminal epidemiological observation that nonsteroidal anti-inflammatory drugs
(NSAIDs) prevent colon and possibly other cancers has spurred novel approaches to cancer …

Chronic inflammation is a risk factor for several gastrointestinal malignancies, including
esophageal, gastric, hepatic, pancreatic and colorectal cancer. It has long been known that …

Background Epidemiologic and laboratory investigations suggest that aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon …

Colorectal cancer is one of the commonest malignancies worldwide. Recently, there has
been much speculation regarding the role of cyclooxygenase-2 (COX-2) suppression in …

Considerable evidence supports the effectiveness of aspirin for chemoprevention of
colorectal cancer (CRC) in addition to its well-established benefits in the prevention of …

Use of nonsteroidal anti‐inflammatory drugs such as aspirin, which are known to inhibit
cyclooxygenase activity, reduces the relative risk of colorectal cancer in humans by 40–50 …

Colorectal cancer (CRC) is one of the most common neoplasia in Western countries and the
second leading cause of cancer-related death. The vast majority of cases belong to sporadic …